Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys

Biochemical Pharmacology

Volumn 78, Issue 6, 2009, Pages 642-647

  Tang, Cuyue ^a   Kuo, Yuhsin ^a   Pudvah, Nicole T ^a   Ellis, Joan D ^a   Michener, Maria S ^a   Egbertson, Melissa ^a   Graham, Samuel L ^a   Cook, Jacquelynn J ^a   Hochman, Jerome H ^a   Prueksaritanont, Thomayant ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Blood brain barrier; Cerebral spinal fluid; P glycoproteins; Rhesus monkeys

Indexed keywords

DRUG; GLYCOPROTEIN P;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; CELL LINE; CEREBROSPINAL FLUID LEVEL; CISTERNA MAGNA; CONTROLLED STUDY; DRUG PENETRATION; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; HUMANS; MACACA MULATTA; MALE; MOLECULAR WEIGHT; ORGANIC CHEMICALS; P-GLYCOPROTEIN; PLASMA; TRANSFECTION;

EID: 67651183605     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.026     Document Type: Article

References (31)

1. Carneheim C., and Ståhle L. Microdialysis of lipophilic compounds: a methodological study. Pharmacol Toxicol 69 (1991) 378-380
2. Khramov A.N., and Stenken J.A. Enhanced microdialysis recovery of some tricyclic antidepressants and structurally related drugs by cyclodextrin-mediated transport. Analyst 124 (1999) 1027-1033
3. Xie R., and Hammarlund-Udenaes M. Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res 15 (1998) 570-575
4. Hinton J.P., and Hudson G. Unbound plasma concentrations may predict neuroprotective brain concentrations: a brain microdialysis and pharmacokinetic study of enadoline in rats. Acta Neurochir Suppl 75 (1999) 7-9
5. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33 (2005) 165-174
6. Maurer T.S., Debartolo D.B., Tess D.A., and Scott D.O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33 (2005) 175-181
7. Shen D.D., Artru A.A., and Adkison K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56 (2004) 1825-1857
8. Venkatakrishnan K., Tseng E., Nelson F.R., Rollema H., French J.L., Kaplan I.V., et al. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos 35 (2007) 1341-1349
9. Liu X., Smith B.J., Chen C., Callegari E., Becker S.L., Chen X., et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34 (2006) 1443-1447
10. Ohe T., Sato M., Tanaka S., Fujino N., Hata M., Shibata Y., et al. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Dispos 31 (2003) 1251-1254
11. He H, Lyons KA, Shen X, Yao Z, Bleasby K, Chan G, et al. Utility of unbound plasma drug levels and Pgp data in prediction of CNS exposure. Xenobiotica 2009, in press.
12. Tang C., Kassahun K., McIntosh I.S., Brunner J., and Rodrigues A.D. Simultaneous determination of urinary free cortisol and 6beta-hydroxycortisol by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry and its application for estimating hepatic CYP3A induction. J Chromatogr B: Biomed Sci Appl 742 (2000) 303-313
13. Jin L., Chen I.W., Chiba M., and Lin J.H. Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. Xenobiotica 33 (2003) 643-654
14. Kumar S., Kwei G.Y., Poon G.K., Iliff S.A., Wang Y., Chen Q., et al. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 304 (2003) 1161-1171
15. Prueksaritanont T., Kuo Y., Tang C., Li C., Qiu Y., Lu B., et al. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34 (2006) 1546-1555
16. Inder T., Neil J., Yoder B., and Rees S. Non-human primate models of neonatal brain injury. Semin Perinatol 28 (2004) 396-404
17. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J 48 (2007) 339-355
18. Williams R., Bokhari S., Silverstein P., Pinson D., Kumar A., and Buch S. Nonhuman primate models of NeuroAIDS. J Neurovirol 14 (2008) 292-300
19. 11C]verapamil. J Pharmacol Exp Ther 316 (2006) 647-653
20. 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 50 (2009) 108-115
21. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49 (2008) 649-656
22. Yamazaki M., Neway W.E., Ohe T., Chen I., Rowe J.F., Hochman J.H., et al. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296 (2001) 723-735
23. Booth-Genthe C.L., Louie S.W., Carlini E.J., Li B., Leake B.F., Eisenhandler R., et al. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. J Pharmacol Toxicol Methods 54 (2006) 78-89
24. Gilberto D.B., Zeoli A.H., Szczerba P.J., Gehret J.R., Holahan M.A., Sitko G.R., et al. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci 42 (2003) 53-59
25. Kim I.W., Booth-Genthe C., and Ambudkar S.V. Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 8 (2008) 193-200
26. Gazzin S., Strazielle N., Schmitt C., Fevre-Montange M., Ostrow J.D., Tiribelli C., et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 510 (2008) 497-507
27. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96 (1999) 3900-3905
28. de Lange E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 56 (2004) 1793-1809
29. Nolte J. Ventricles and cerebrospinal fluid. The human brain: introduction to its functional anatomy. 5th ed. (2002), Mosby, Inc. pp. 98-118
30. Watson J.M., Wright S., Lucas A.J., Clarke K.L., Viggers J., Cheetham S., et al. Receptor Occupancy and Brain Free Fraction. Drug Metab Dispos (2009) Jan 21 [Epub ahead of print]
31. Lin J.H. How significant is the role of P-glycoprotein in drug absorption and brain uptake?. Drugs Today 40 (2004) 5-22